UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Cancer cell, ISSN 1535-6108, 09/2015, Volume 28, Issue 3, pp. 285 - 295
Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Tumor Microenvironment - immunology | Animals | Neoplasms - immunology | Antibodies - immunology | Cell Line, Tumor | Ligands | Mice | Programmed Cell Death 1 Receptor - immunology | Receptors, IgG - immunology | B7-H1 Antigen - immunology | Index Medicus
Journal Article
Nature (London), ISSN 0028-0836, 11/2014, Volume 515, Issue 7528, pp. 577 - 581
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Antigens, Neoplasm - genetics | Sarcoma - immunology | Antigens, Neoplasm - immunology | Antibodies, Monoclonal - therapeutic use | Male | Vaccines, Synthetic - therapeutic use | Epitopes - genetics | Sarcoma - therapy | Cancer Vaccines - therapeutic use | Animals | Immunotherapy | Mice | CD8-Positive T-Lymphocytes - immunology | Cell Cycle Checkpoints - immunology | Care and treatment | Sarcoma | Analysis | Development and progression | Drug therapy | Health aspects | Antigenic determinants | Cancer | Antigens | Peptides | Lymphocytes | Mutation | Tumors | Index Medicus
Journal Article
Nature reviews. Cancer, ISSN 1474-175X, 08/2015, Volume 15, Issue 8, pp. 457 - 472
Life Sciences & Biomedicine | Oncology | Science & Technology | Tumor Microenvironment - immunology | Neoplasms - therapy | Animals | Neoplasms - immunology | Humans | Immunotherapy | Biomarkers, Tumor - metabolism | Antineoplastic Agents - pharmacology | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Combined Modality Therapy | Molecular Targeted Therapy | Care and treatment | Pharmacology, Experimental | Oncology, Experimental | Innovations | Drug targeting | Research | Methods | Drug synergism | Cancer | Index Medicus
Journal Article
Cancer research (Chicago, Ill.), ISSN 0008-5472, 02/2012, Volume 72, Issue 4, pp. 917 - 927
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Tumors | Antibodies - therapeutic use | Antigens, CD - immunology | Neoplasm Transplantation | Mice, Inbred C57BL | Neoplasms, Experimental - therapy | Programmed Cell Death 1 Receptor - physiology | CD4-Positive T-Lymphocytes - immunology | Drug Synergism | Neoplasms, Experimental - pathology | Animals | Immune Tolerance - immunology | Neoplasms, Experimental - immunology | Cell Line, Tumor | Antigens, CD - physiology | Mice | Programmed Cell Death 1 Receptor - immunology | Tumor Escape - immunology | Index Medicus | T cells | LAG-3 | PD-1 | tumor | immunotherapy
Journal Article
Cancer immunology research, ISSN 2326-6066, 07/2013, Volume 1, Issue 1, pp. 32 - 42
Oncology | Immunology | Life Sciences & Biomedicine | Science & Technology | Colonic Neoplasms - therapy | Cricetulus | Antibodies, Monoclonal - pharmacology | Mice, Inbred C57BL | Random Allocation | CTLA-4 Antigen - immunology | T-Lymphocytes, Regulatory - immunology | Animals | Colonic Neoplasms - immunology | Immunoglobulin G - immunology | Immunoglobulin G - pharmacology | Female | Mice | Mice, Inbred BALB C | Antibodies, Monoclonal - immunology | CHO Cells | Disease Models, Animal | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 06/2012, Volume 366, Issue 26, pp. 2443 - 2454
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Neoplasms - metabolism | Antibodies, Monoclonal - pharmacology | Humans | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - metabolism | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Melanoma - drug therapy | Adult | Female | Ligands | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Carcinoma, Renal Cell - drug therapy | Prostatic Neoplasms - drug therapy | Drugs | Dose-response relationship (Biochemistry) | Immune response | Anti-antibodies | Dosage and administration | Product/Service Evaluations | Regulation | Research | Drug therapy | Cancer | Fees & charges | Kidneys | PD-1 protein | Stock options | Laboratories | Toxicity | Tumor cells | Body weight | Lung cancer | Colorectal carcinoma | Colorectal cancer | Melanoma | Licenses | Lymphocytes T | Patients | Castration | Renal cell carcinoma | PD-L1 protein | Antitumor activity | Prostate cancer | Drug dosages | Prostate | Tumors | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 03/2020, Volume 130, Issue 3, pp. 1405 - 1416
Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Animal models | CD137 antigen | PD-1 protein | CD8 antigen | Cytotoxicity | Genomes | Lymphocytes T | Ribonucleic acid--RNA | Proteins | Liver cancer | CTLA-4 protein | Immune checkpoint | Cell death | Lymphocytes | Immunotherapy | PD-L1 protein | Antitumor activity | Ligands | Apoptosis | Tumors | Cancer | Index Medicus | Abridged Index Medicus
Journal Article